Agilent Technologies arrives at its August 26 earnings release on the back of a 20% monthly rally — the strongest momentum case the stock has built in recent quarters, and the one the print now has to justify.
The stock closed at $159 on August 21, up 7% on the week, with the mean analyst price target sitting at $160.89 — barely above the current price. That near-convergence matters. Morgan Stanley raised its target to $175 on August 12, maintaining Overweight, and that remains the most constructive institutional call on the tape. Most other targets cluster in the $148–$165 range, meaning the Street was already pricing in a meaningful recovery before this final leg higher. Options positioning has drifted more cautious as the stock has risen: the put/call ratio is running at 0.59, about 1.6 standard deviations above its 20-day average of 0.54. That's not an extreme hedge, but it is a signal that some participants are paying for downside protection into a print where the upside from analyst targets is now thin.
The short side of the ledger adds little pressure to that picture. Short interest remains at 2.0% of the free float — exactly where it settled after the near-25% single-session unwind earlier in August, and there has been no meaningful rebuilding since. Borrow availability is effectively unlimited, and the cost to borrow is running at 0.42%, well within its recent range. The ORTEX short score has eased further to 31.5, comfortably away from any bearish extreme. Short sellers are not a factor heading into this print.
The bull case rests on Agilent's diversity — biopharmaceutical, chemical, and advanced materials exposure — and the expectation that a recovering life sciences capex cycle translates into better-than-feared top-line growth. The bear case is more about valuation than fundamentals: at roughly 23x trailing earnings and an EV/EBITDA near 19x, the stock has re-rated sharply on the back of optimism, and any guidance that falls short of the implied trajectory embedded in those multiples could be uncomfortable. Insider activity provides no real directional read — recent sales have been small and routine, well below any significance threshold.
The August 26 print is ultimately a test of whether Agilent's operational recovery is durable enough to hold a stock that has already run 20% in a month — and whether guidance can stretch the gap between the current price and the Street's most constructive targets.
See the live data behind this article on ORTEX.
Open A on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
